To help advance care for the littlest orthopedic patients, the spine company NuVasive, Inc. recently announced the launch of a monthly podcast, MAGEC Matters, featuring interviews with leading pediatric deformity surgeons.
NuVasive Launches Pediatric Spinal Deformity Podcast
1 min read Premium comments
Secondary
“At NuVasive, we are not only passionate about the world-class innovation we are bringing to market to help improve pediatric spinal deformity, but we’re also passionate about the education and research that is necessary to provide surgeons with the information they need to advance the care options available to pediatric patients,” said Jason Hannon, NuVasive’s president and chief operating officer, in the company’s May 2, 2017 news release.
“We’ve made tremendous investments in building a comprehensive pediatric deformity portfolio with our MAGEC system, RELINE posterior fixation platform and PRECICE limb lengthening system. By supporting events such as EPOSNA (Pediatric Orthopaedic Society of North America), we are able to connect surgeons from around the world and help improve the lives of children.”
Jason Hannon told OTW, “The idea of a MAGEC focused podcast came from collaboration between our surgeon partners, and our marketing team. We discussed how to best share the latest and greatest information regarding our MAGEC system in an easily accessible way, while using a modern media format. The launch of our podcast series reflects our continued commitment to support the educational and aspirational goals of our surgeons, providing new tools to bring awareness of innovative technology to help more patients. Our ‘MAGEC Matters’ podcast—available on iTunes or SoundCloud—is designed for the medical community, but also benefits our sales team, patients and their families.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.